FOR IMMEDIATE RELEASE

BMSystems receives a Bio-IT World Best Practices Award from the Cambridge Healthtech Institute.

PRESS RELEASE: Paris, July 28, 2009: We are proud to announce that, following selection by a prestigious US industry panel, BMSystems is, this year, the only European company to be granted a Bio-IT World Best Practices Award, recognizing the outstanding contribution made by our innovative CADI™ model building approach to a collaborative research program, with the CEA-SEPIA research team, on neurodegenerative disorders.

Besides leading to the world's first /in-vivo/ validation of an in-silico model describing the mechanisms associated with the pathogenesis and the progression of Creutzfeldt-Jakob disease (publication submitted), a second CADI™ modeling program with the same CEA-SEPIA research team also allowed the discovery of novel therapeutic approaches in the treatment of poorly served CNS diseases (patent pending).

This prestigious industrial award is a strong international acknowledgement of the excellence and efficacy of our work. By granting BMSystems a Bio-IT World Best Practices Award, the US industry selection panel recognizes and confirms that our CADI™ model building approach and its innovative, synergic interplay between experimental and integrative biology, is a remarkably effective R&D booster in life sciences, leading to directly exploitable discoveries.

In addition, the two team leaders (experimental and integrative biology) have been selected to present their original and productive work at the third edition of the European conference Be Live IT in Brussels (October 20-21, 2009). www.beliveit.org

Do not hesitate to visit our website www.bmsystems.net and to contact us for more information.

Our company will participate to Eurobio in Lille: www.eurobio-event.com and Bio Europe in Vienna/ www.ebdgroup.com/bioeurope

Best regards

Manuel Gea

CEO and Co-founder
26, rue Saint Lambert
75015 – Paris,
France
manuel.gea@bmsystems.net
www.bmsystems.net

About Bio-Modeling Systems

BMSystems is a research-based biotech company that creates CADI™ (Computer Assisted Deductive Integration) models to harness & explain the non-linear mechanisms of life and diseases, thus reveal "pertinent" biomarkers & therapeutic targets

- BMSystems published in 2003 the world's first in-vitro independently validated in-silico model of a complex human disease, hRas-dependent breast cancer progression, with INSERM Unit 553.
- BMSystems completed the first complex human disease (Creutzfeldt-Jakob) CADI™ model validated in *vi-vo* with CEA Life Sciences Dept
- CADI ™ methodologies and tools, based on negative selection concepts, were invented in 2002 by Dr. François Iris, founder, Chairman and CSO of the company.
- CADI™ models belong to the non-mathematical holistic and heuristic class of models. They can describe the dynamics of a pathological process and/or the pathological mechanisms vs. control.

CADI™ modeling approach has repeatedly allowed researchers to take the best possible decisions for the best possible results in a minimum of time and resources.

BMSystems' current achievements, in addition to multiple publications:

- 8 CADI™ models produced in 5 major medical areas, (CNS/ PNS, Oncology, Infection / Immunology, Tissue differentiation, Metabolism),
- First complex human disease (Creutzfeldt-Jakob) CADI™ model validated *in vi-vo* with CEA Life Sciences Dept Fontenay-aux Roses
- 1 patent in "psychiatric disorders" in collaboration with CEA Life Sciences Dept,
- 3 patents filed in "therapeutics for infectious diseases" and "nanobiotech",
- 2 technological platforms (pre-clinical evaluation for psychotropic molecules and industrial biotech),
- 1 operational spin-off in Biodefense/Biosecurity (infectious threats),
- 2 bacterial strains under development for "Synthons", the major industrial biotech collaborative R&D program in France,

The company generates highly attractive businesses, through contractual/collaborative research programs, and is active in the following markets: Pharma-Biotech, Energy - Chemicals – Environment and biodefense-biosecurity-nanobiotech with its spin-off Pherecydes-Pharma.

DOMAINS	CADI™ PROGRAMS
CNS / Peripheral Nervous System	Neurodegenerative (Creutzfeldt-Jakob[2], Alzheimer[1]) diseases, Psychiatric disorders[5], Pain[5], Migraine[5], Fibromyalgia[5]
Oncology	Breast cancer[3], Tamoxifen resistance[3], Metastasis[2]
Infection / Immunology	Antibacterial bio-agent[4], Hepatitis C[5], CFS (Chronic Fatigue Syndrome)[1]
Tissue differentiation	Adipocytes growth control[5], Müllerian regression[2]
Metabolism	Hypercholesterolemia[5], Metabolic Syndrome[5]
Industrial biotech	Program Synthons[2]: leading Industrial biotech collaborative R&D platform
Proteins diversification engine	CADI™-TAPE Process[3] to improve antibodies, enzymes, long peptides etc..
Nanobiotech, Phages	Pherecydes-Pharma[4], BMSystems' spin-off, Nano-biotechnologies & nano-devices through phage genetic engineering.

1: Models ready for experimental evaluation; 2: Experimentally validated models;
3: Experimentally validated and published models; 4: Experimentally validated and industrially exploited; 5: Proto-Models (positive feasibility study),

<u>*About the Best Practices Awards*</u>

**BIO-IT WORLD ANNOUNCES WINNERS OF ITS
2009 BEST PRACTICES AWARDS**

Needham, Mass. – April 29, 2009 – *Bio-IT World* magazine today announced the winners of its fifth Best Practices Awards program. Grand Prize winners within eight life sciences awards categories include Genentech, Wyeth Research, Amgen, the Broad Institute of MIT and Harvard, Vanderbilt University, Merck & Company, Abbot Laboratories, GlaxoSmithKline, and the National Center for Genome Resources.

Established in 2003, *Bio-IT World's* Best Practices Awards Program recognizes these organizations for their outstanding innovations and excellence in the use of technologies, practices, and novel business strategies that will advance drug discovery, development, biomedical research, and clinical trials. The competition's first Judges' Prize goes to the Children's Hospital of Philadelphia for their Pediatric Knowledgebase and the recipient of the Editor's Choice Award is AstraZeneca, nominated by BioWisdom, for their Safety Intelligence Program.

Bio-IT World's Best Practices Awards ceremony was held last night at the World Trade Center in Boston, MA, co-located with CHI's Seventh Annual Bio-IT World Conference & Expo. Key industry leaders attended the ceremony, which featured a keynote speech by Michael Cariaso, senior scientific consultant, BioTeam.

Phillips Kuhl, co-founder and president of Cambridge Healthtech Institute (CHI), started the evening with welcoming comments and introduced Kevin Davies, Ph.D., editor-in-chief of *Bio-IT World*, the flagship publication of CHI, to initiate the presentation of awards.

"These awards spotlight examples of the most outstanding innovations, technologies and practices in the fields of biomedical research, drug development and clinical research—spotlighting the tools and strategies that can make a difference in the conduct of basic and clinical research, speeding the drug discovery pipeline, and changing the way we generate, share and analyze data and knowledge," said Kevin Davies, editor in chief of Bio-IT World.

A peer-review panel of 14 expert judges reviewed a record 72 detailed submissions from organizations ranging from large pharmaceutical and biotechnology companies, academic institutions, to niche service providers, detailing best practices in one of seven categories. Allison Proffitt, managing editor of *Bio-IT World*; Gerard Sample, senior product marketing manager, BlueArc; Grant Stephen, CEO Tessella; Phillips Kuhl; and Kevin Davies presented the Grand Prize trophies to the following organizations within these categories:

- *Basic Research:* **National Center for Genome Resources**.

© Bio-Modeling Systems 2009 www.bmsystems.net

NCGR's Schizophrenia Genome Project

- ***Clinical Trials Management:*** **Genentech**
Nominated by ePharmaSolutions, the Clinical Trial Portal

- ***Clinical Trials Design:*** **Wyeth Research**
Nominated by Tessella, design of adaptive clinical trials using Adaptive Design Explorer

- ***Drug Discovery & Development:*** **Amgen**
Nominated by Genedata, Amgen Lead Discovery Informatics

- ***IT Informatics:*** **The Broad Institute of MIT and Harvard**
CellProfiler

- ***Knowledge Management***: **Vanderbilt University**
Nominated by ActiveHealth Management, A computerized, clinically intelligent system to deliver clinical alerts to physicians and their patients improves care and lowers health care costs.

- ***Knowledge Management, Pharma:*** **Merck & Co. and Abbott Laboratories**
Nominated by Accelrys, Biological Knowledge Management: Registration, Association, and Sharing

- ***Translational and Personalized Medicine***: **GlaxoSmithKline**
Nominated by ProSanos Corporation, SÆfty Works: Leveraging Observational data to explore the effects of medicines

Honorable mention is given to the following entries:

- **CEA (Commissariat à l'Energie Atomique)** *nominated by* **Bio-Modeling Systems**

- **AstraZeneca** *nominated by* **Medidata Solutions**

- **Pathworks Diagnostics** *nominated by* **Univa UD**
-
- **Genentech** *nominated by* **Dolcera**

- **AstraZeneca** *nominated by* **Thermo Fisher Scientific**

Criteria and Judging

Awards finalists and winners were selected for their innovative utilization of bio-IT, including life science equipment, informatics and information technology, on a project or organizational level to achieve significantly improved results (i.e. improvements in productivity or conceptual breakthroughs in scientific understanding or process methodology). The peer review judges applied several criteria to make their decisions, such as innovation, significance, and industry impact. Entries were accepted from R&D and scientific facilities and labs in pharmaceutical companies, biotech companies, academia, government, medical or related institutions and organizations, as well as public and private research labs. For information on *Bio-IT World's* 2009 Best Practices Awards, please email marketing_chmg@chimediagroup.com. The July/August issue of *Bio-IT World* will feature editorial on Best Practices, highlighting award winners, profiling entrants, event coverage and the enabling technologies used by the many companies.

The 2009 Best Practices Awards were organized by *Bio-IT World* editors, including Managing Editor Allison Byrum Proffitt, Editor-in- Chief Kevin Davies, and key marketing & operations staff members of Cambridge Healthtech Media Group, a division of CHI. Joining the editors in judging the entries was a distinguished panel of experts, including:

- Stephen Fogelson, Devolotron
- Stan Kachnowski, Health Information and Technology Lab
- Jerry Schindler, Merck
- Sandy Aronson, Harvard Medical School
- Ernie Bush, Cambridge Healthtech Associates
- Joseph Cerro, Consultant
- Al Doig, CHI Insight Pharma Reports
- Bill Van Etten, BioTeam
- Noemi Greyzdorf, IDC
- Jim Kremidas, Quintiles
- Alan Louie, Health Industry Insights/IDC
- Eric Neumann, Clinical Semantics Group
- Deepak Thakkar, SGI
- Phillips Kuhl, Cambridge Healthtech Institute

Sponsors

Sponsors generously underwriting the 2008 Best Practices Awards are Tessell, BlueArc Corporation, and Lilly Singapore Center for Drug Discovery.

The winners will be profiled in the July/August issue of *Bio-IT World*.

The 2010 *Bio-IT World* Best Practices competition will begin soliciting entries in October 2009.

About Bio-IT World

Bio-IT World (www.bio-itworld.com), the flagship publication of Cambridge Healthtech Institute (CHI), is the leading source of news on technology and strategic innovation in drug discovery, development, and clinical trials. *Bio-IT World* explores the tools and results of predictive biology as the industry adapts to the new world of personalized medicine. *Bio-IT World* has won 34 national and regional awards, more than any other magazine covering the life sciences industry. CHI offers a suite of published resources through a new division—Cambridge Healthtech Media Group—that includes *Bio-IT World* magazine, numerous topic-specific eNewsletters, white papers, webcasts, podcasts, conferences, and the *Bio-IT World* Best Practices Awards. The magazine is based in Needham, MA.

About Cambridge Healthtech Institute (CHI)

Founded in 1992, Cambridge Healthtech Institute (www.chicorporate.com) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech, academic, and niche service provider organizations. CHI's integrated life science portfolio of products and services includes Cambridge Healthtech Institute Conferences, Pharmaceutical Strategy Series, Barnett International, Insight Pharma Reports, Marketing Services, Meeting Planners, and Cambridge Healthtech Media Group, which includes numerous eNewsletters, *Bio-IT World* magazine, as well as Lead Generation Programs.